公开(公告)号：US20180085370A1

公开(公告)日：2018-03-29

申请号：US15659526

申请日：2017-07-25

申请人： Gilead Sciences, Inc.

发明人： Manoj C. Desai ,  Randall L. Halcomb ,  Paul Hrvatin ,  Hon Chung Hui ,  Ryan McFadden ,  Paul A. Roethle ,  Hong Yang

IPC分类号： A61K31/519 ,  A61K38/21 ,  C07D475/06 ,  A61K38/16 ,  A61K31/708 ,  A61K31/7072 ,  A61K31/7056 ,  A61K31/683 ,  A61K31/573 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/551 ,  A61K31/527 ,  C07D403/12 ,  C07D475/10 ,  C07D487/04 ,  C07D475/12 ,  C07D475/08

CPC分类号： A61K31/519 ,  A61K31/527 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/573 ,  A61K31/683 ,  A61K31/7056 ,  A61K31/7072 ,  A61K31/708 ,  A61K38/16 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  C07D403/12 ,  C07D475/06 ,  C07D475/08 ,  C07D475/10 ,  C07D475/12 ,  C07D487/04 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/391 ,  Y02A50/393 ,  Y02A50/395

摘要： Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

公开(公告)号：US09907804B2

公开(公告)日：2018-03-06

申请号：US15056610

申请日：2016-02-29

申请人： WisTa Laboratories Ltd.

发明人： Colin Marshall ,  Scott Clunas ,  John Mervyn David Storey ,  James Peter Sinclair ,  Thomas Craven Baddeley ,  Ahtsham Ishaq ,  Michael Simpson ,  Craig Williamson ,  Barry Alan Wood ,  Claude Michel Wischik ,  Charles Robert Harrington ,  Janet Elizabeth Rickard ,  David Horsley ,  Yin Sze Loh ,  Karrar Ahmad Khan ,  Christopher Paul Larch

IPC分类号： A61K31/5415 ,  A61K9/00 ,  A61K9/20 ,  A61L2/00 ,  C07D279/20 ,  A61K9/28 ,  C07C309/04 ,  C07C309/05 ,  C07C309/30 ,  C07C309/35 ,  C07C303/32

CPC分类号： A61K31/5415 ,  A61K9/0053 ,  A61K9/2095 ,  A61K9/2893 ,  A61L2/0052 ,  C07C303/32 ,  C07C309/04 ,  C07C309/05 ,  C07C309/30 ,  C07C309/35 ,  C07D279/20 ,  Y02A50/393 ,  Y02A50/411

摘要： Disclosed are compounds of general formula (I): and pharmaceutically acceptable salts thereof, formulations, methods and uses in, for example, the treatment of disease.

公开(公告)号：US09884032B2

公开(公告)日：2018-02-06

申请号：US15060320

申请日：2016-03-03

申请人： PROPONENT BIOTECH GMBH

发明人： Bettina Ernst

IPC分类号： A61K31/19 ,  A61K9/00 ,  A61K31/192 ,  A61K31/215 ,  A61K31/222 ,  A61K31/25 ,  A61K31/22

CPC分类号： A61K31/19 ,  A61K9/0043 ,  A61K9/0056 ,  A61K9/006 ,  A61K31/192 ,  A61K31/215 ,  A61K31/22 ,  A61K31/222 ,  A61K31/25 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  Y02A50/463 ,  Y02A50/465

摘要： The present invention relates to short chain fatty acids (SCFA) for use in transmucosal administration to a subject for the prevention, attenuation or treatment of a disease or disorder associated with a compromised Th1 immune response and/or an unwanted Th2 or Th2-like immune response by modulating a Th2 immune response towards a Th1 immune response, particularly for the treatment, prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders.

公开(公告)号：US20180028449A1

公开(公告)日：2018-02-01

申请号：US15635169

申请日：2017-06-27

申请人： Ansun Biopharma, Inc.

发明人： Michael P. Malakhov ,  Fang Fang

IPC分类号： A61K9/16 ,  A61K9/19 ,  A61K9/50 ,  A61K31/198 ,  A61K31/337 ,  C12N15/113 ,  C12N9/96 ,  C12N7/00 ,  C07K14/765 ,  C07K9/00 ,  C07D305/14 ,  A61K38/48 ,  A61K38/47 ,  A61K38/46 ,  A61K38/42 ,  A61K38/38 ,  A61K38/18 ,  A61K38/17 ,  A61K38/16 ,  A61K38/14 ,  A61K38/12 ,  A61K38/08 ,  A61K35/76 ,  A61K31/724 ,  A61K31/721 ,  A61K31/7036 ,  A61K31/65 ,  A61K31/5575 ,  A61K31/557 ,  A61K31/555 ,  A61K31/43 ,  A61K31/405 ,  A61K31/343 ,  A61K9/00

CPC分类号： A61K9/1682 ,  A61K9/0048 ,  A61K9/0075 ,  A61K9/1652 ,  A61K9/1658 ,  A61K9/19 ,  A61K9/5089 ,  A61K31/198 ,  A61K31/337 ,  A61K31/343 ,  A61K31/405 ,  A61K31/43 ,  A61K31/555 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/65 ,  A61K31/7036 ,  A61K31/721 ,  A61K31/724 ,  A61K35/76 ,  A61K38/08 ,  A61K38/12 ,  A61K38/14 ,  A61K38/168 ,  A61K38/1709 ,  A61K38/1808 ,  A61K38/38 ,  A61K38/385 ,  A61K38/42 ,  A61K38/465 ,  A61K38/47 ,  A61K38/4826 ,  C07D305/14 ,  C07K9/008 ,  C07K14/765 ,  C12N7/00 ,  C12N9/96 ,  C12N15/113 ,  C12N15/1137 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/50 ,  C12N2330/30 ,  C12N2770/00021 ,  C12N2770/00051 ,  C12Y301/21001 ,  C12Y301/27005 ,  C12Y302/00 ,  C12Y302/01017 ,  C12Y302/01018 ,  C12Y304/21004 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  Y02A50/401 ,  Y02A50/402 ,  Y02A50/411 ,  Y02A50/469 ,  Y02A50/47 ,  Y02A50/471 ,  Y02A50/478 ,  Y02A50/481 ,  Y02A50/483 ,  Y02A50/49 ,  Y02A50/491

摘要： Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

公开(公告)号：US09801890B2

公开(公告)日：2017-10-31

申请号：US15419763

申请日：2017-01-30

申请人： WisTa Laboratories Ltd.

发明人： John Mervyn David Storey ,  James Peter Sinclair ,  Colin Marshall ,  Han Wan Tan ,  Claude Michel Wischik

IPC分类号： A61K31/5415 ,  G01N33/52 ,  A61K49/00

CPC分类号： A61K31/5415 ,  A61K9/0019 ,  A61K49/006 ,  C07D279/18 ,  C09B19/02 ,  G01N33/52 ,  Y02A50/393

摘要： This disclosure pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallization (RX). Also disclosed resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases.

公开(公告)号：US09744229B2

公开(公告)日：2017-08-29

申请号：US14263752

申请日：2014-04-28

申请人： The Trustees of the University of Pennsylvania

发明人： David B. Weiner ,  Mathew P. Morrow

IPC分类号： A61K39/285 ,  C07K14/54 ,  A61K38/20 ,  C12N7/00

CPC分类号： A61K39/285 ,  A61K38/20 ,  C07K14/54 ,  C12N7/00 ,  Y02A50/393

摘要： Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.

公开(公告)号：US20170226511A1

公开(公告)日：2017-08-10

申请号：US15036451

申请日：2014-11-13

申请人： NATIONAL UNIVERSITY OF SINGAPORE

发明人： Mah Lee Mary NG ,  Krupakar PARTHASARATHY ,  Jin Shun Anthony CHUA ,  Hui Yu Haydan YEO

IPC分类号： C12N15/115 ,  A61K45/06 ,  G01N33/569 ,  A61K31/713

CPC分类号： C12N15/115 ,  A61K31/7115 ,  A61K31/713 ,  A61K45/06 ,  C12N2310/16 ,  C12N2310/33 ,  C12N2310/3513 ,  C12N2310/3517 ,  C12N2320/31 ,  C12N2320/50 ,  G01N33/56983 ,  G01N2333/185 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/393 ,  Y02A50/395

摘要： The present invention relates to nucleic acids. In particular, it relates to aptamers capable of binding to a flavivirus structural protein or a flavivirus non-structural protein, useful as therapeutics for preventing, treating and/or diagnosing a flavivirus infection in a patient.

公开(公告)号：US20170173001A1

公开(公告)日：2017-06-22

申请号：US15450840

申请日：2017-03-06

申请人： Inflammatory Response Research, Inc.

发明人： Bruce Chandler May

IPC分类号： A61K31/495 ,  A61K45/06 ,  A61K31/47

CPC分类号： A61K31/495 ,  A61K31/47 ,  A61K45/06 ,  A61P25/00 ,  A61P25/16 ,  A61P25/28 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393 ,  Y02A50/395 ,  Y02A50/411 ,  A61K2300/00

摘要： The embodiments described herein include methods and formulations for treating viruses and diseases that are exacerbated by inflammatory responses in the body. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.

公开(公告)号：US20170128483A1

公开(公告)日：2017-05-11

申请号：US15127277

申请日：2015-03-24

申请人： Ruprecht-Karls-Universitat Heidelberg

发明人： Wolfgang FISCHL ,  Eliana ACOSTA ,  Alessia RUGGIERI ,  Ralf BARTENSCHLAGER

IPC分类号： A61K31/7076 ,  A61K31/166 ,  G01N33/50 ,  A61K31/427 ,  A61K31/155 ,  A61K31/4709 ,  A61K45/06 ,  A61K31/381

CPC分类号： A61K31/7076 ,  A61K31/155 ,  A61K31/166 ,  A61K31/381 ,  A61K31/427 ,  A61K31/435 ,  A61K31/437 ,  A61K31/4709 ,  A61K45/06 ,  G01N33/502 ,  G01N2500/10 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/393 ,  Y02A50/395

摘要： The present invention relates to inhibitor(s) or antagonist(s) of PADI4 (peptidyl arginine deiminase, type IV), PPARδ (peroxisome proliferator-activated receptor delta), GCKR (glucokinase regulatory protein), and/or P2X4R (purinergic receptor P2X, ligand-gated ion channel 4) for the use as anti-viral agent(s) as well as for the use in the prevention and/or treatment of infection(s) with virus(es) of the Flaviviridae family, such as Dengue virus and hepatitis C virus (HCV). The present invention further relates to pharmaceutical compositions or kits comprising said inhibitor(s)/antagonist(s) and methods of preventing and/or treating infection(s) with virus(es) of the Flaviviridae family. The present invention further relates to methods of screening for antiviral agent(s). The present invention relates to PADI4 (peptidyl arginine deiminase, type IV), PPARδ (peroxisome proliferator-activated receptor delta), GCKR (glucokinase regulatory protein), and/or P2X4R (purinergic receptor P2X, ligand-gated ion channel 4) for the use in diagnosis, prevention and/or treatment of infection(s) with virus(es) of the Flaviviridae family, preferably as targets for antiviral treatment or as screening targets.

公开(公告)号：US09642889B2

公开(公告)日：2017-05-09

申请号：US14719242

申请日：2015-05-21

申请人： Selcia Limited ,  Gilead Sciences, Inc.

发明人： Caroline Aciro ,  Jean Yves Chiva ,  David Kenneth Dean ,  Adrian John Highton ,  Petr Jansa ,  Andrew John Keats ,  Linos Lazarides ,  Richard Mackman ,  Karine G. Poullennec ,  Adam James Schrier ,  Dustin Scott Siegel ,  Victoria Alexandra Steadman ,  Greg Watt

IPC分类号： A61K38/21 ,  A61K38/12 ,  C07D487/08 ,  C07D498/08 ,  C07D498/18 ,  C07D498/22 ,  A61K39/29 ,  A61K45/06 ,  C07K5/02 ,  A61K39/05 ,  A61K38/15 ,  A61K38/00

CPC分类号： C07K5/0202 ,  A61K38/00 ,  A61K38/12 ,  A61K38/15 ,  A61K39/05 ,  A61K39/29 ,  A61K45/06 ,  C07D487/08 ,  C07D498/08 ,  C07D498/18 ,  C07D498/22 ,  C07K5/02 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/391 ,  Y02A50/393 ,  Y02A50/395

摘要： Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.